N/A N=9 Woodsmoke Particulate + Hypertonic Saline
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -0.04; -0.5 percent neutrophils — p=> 0.99
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Aerosol Particle Concentrations Among Different Oxygen Devices for Spontaneous Breathing Patients With Tracheostomy
Transmission, Patient-Professional
Primary: Aerosol Particle Concentrations With Size of 1-3 Micrometer at 1 Foot Away From the Patient — 13000; 11000; 10000; 12000 particles/m3
N/A N=60 Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
Lung Diseases · Medication Compliance
Primary: Forced Oscillation Technique (FOT) Measures — 4.4; 3.7; 1.0; 0.6 resonant frequency
Phase 2 N=12 Woodsmoke Particulate + Prednisone
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -2.62; 5.45 percent neutrophils — p=0.24
N/A N=50 Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function
Abnormality, Respiratory System · Autonomic Nervous System
Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values
N/A N=22 Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Device Tidal Volume — 180 mL
N/A N=92 Respiratory Dysregulation and Breathing Training in Anxious Outpatients
Anxiety
Primary: Episodic Anxiety Scale — 8.1; 9.0; 14.3 units on a scale
Phase 2 N=30 High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer
Advanced Cancers
Primary: Number of Participants Completing Study Intervention — 7; 10; 3; 5 Participants
N/A N=29 Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
Amyotrophic Lateral Sclerosis (ALS) · Neuromuscular Diseases
Primary: Percent Change in Maximal Inspiratory Pressure (MIP) — 0.3; -3.1; -4.8; -5.0 percentage change in MIP from baseline
N/A N=20 Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Diagnostic Bronchoscopy
Bronchoscopy
Primary: Lowest Intraoperative Peripheral Oxygen Saturation (SpO2) — 94.7; 98.7 percentage of oxygen — p=0.09
N/A N=64 Breathing Retraining for Asthma Trial of Home Exercises for Teenagers
Adolescent Behavior · Asthma
Primary: Asthma-specific Quality of Life — 65.4; 65.1; 66.7; 67.4 score on a scale
N/A N=317 Obstructive Sleep Apnea in World Trade Center Responders
Obstructive Sleep Apnea
Primary: Adherence to CPAP Pre-crossover — 1; 0.89 Hours/night
Phase 4 N=40 Effect of Neuromuscular Blockade and Reversal on Breathing
Respiratory Insufficiency
Primary: Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response) — 0.66; 0.43; 0.54; 0.34 L/min/% desaturation
Phase 1 N=55 Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Hypercapnia · Ventilatory Depression
Primary: Part 1 - Minute Ventilation at the 55 mm Hg End Tidal Carbon Dioxide (CO2) Point (VE55) on Day 1 for Oxycodone Combined With Midazolam and Oxycodone Alone. — 21.9; 24.1…
N/A N=92 Determinants of Age Related Breathing Instability During Non-Rapid-Eye-Movement (NREM) Sleep
Sleep Apnea · Age
Primary: Apneic Threshold (AT) and Carbon-dioxide (CO2) Reserve — 39.8; 36.7; -4.1; -2.6 mm Hg — p=<0.05
N/A N=16 The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing
Chronic Obstructive Pulmonary Disease
Primary: Intensity of Breathlessness — 80.8; 77.9 units on a scale
N/A N=99 A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients
Chronic Obstructive Pulmonary Disease
Primary: Breathlessness — 0.68; 0.71; 0.34; 0.83 score on a scale
N/A N=35 Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
COPD Exacerbation
Primary: Change in Exhaled Breath Metabolites — 3298 breath metabolites
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
N/A N=25 Neurostimulation for the Relief of Acute Bronchoconstriction
Asthma
Primary: Safety- Number of Participants With Adverse Events — 16 Participants
N/A N=31 Hemodynamics Response to Upper Airway Obstruction in Marfan Syndrome
Sleep-disordered Breathing · Snoring
Primary: Pleural Pressure (Pes) — 9.3; 4.4 mmHg
N/A N=382 Assessment of Novel Respiratory Protective Devices in Healthcare
Comfort · Tolerability
Primary: To Collect Healthcare Worker Feedback About Perceived Comfort of Novel Respirator Designs — 5.0; 4.6; 3.7; 4.0 units on a scale
N/A N=60 Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure
Acute Respiratory Insufficiency
Primary: Mask Comfort (as Determined by the Visual Analog Scores 1 Being Least, 10 Being Most) — 3.2; 3.3 units on a scale
N/A N=30 In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Activity Endurance Time — 7.24; 13.38 minutes — p=<0.05
N/A N=1,333 Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Pulmonary Arterial Hypertension
Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
N/A N=38 Assessing Inflammatory and Behavioral Pathways Linking PTSD to Increased Asthma Morbidity in WTC Workers
Asthma · PTSD
Primary: PTSD Checklist for DSM-5 (PCL-5) — 39.2; 36.4; 32.9; 34.3 score on a scale
N/A N=133 Mechanisms of Upper Airway Obstruction
Obstructive Sleep Apnea
Primary: Pharyngeal Critical Pressure (Pcrit) — 1.26; -1.42; -1.06 cm H2O — p=.80
Phase 4 N=66 The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
Exercise-induced Bronchoconstriction (EIB)
Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Postdose — 15.35; 20.00 Percent fall in FEV1 — p=0.020